Evaluation of rare diseases policy performance of oecd countries using mcdm methods

Ince, Özgür; Pak, Merve Deniz

doi:10.1016/j.hlpt.2021.100537

Cited by 7 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As stated in the study by Ince and Pak Güre (25), rare diseases policies in Turkey are quite limited and there is no national plan developed and implemented for rare diseases yet. While more than 100 orphan drugs are covered by reimbursement in many countries such as the USA, Netherlands, Germany and France (25), only 34 orphan drugs are covered in Turkey (26). In addition, while there are only 6 different screening programs for rare diseases in Turkey, there are 28 different programs in Poland, 20 in the Netherlands, 15 in Germany and 5 in France.…”

Section: Discussionmentioning

confidence: 99%

Out-of-pocket healthcare expenditures of Turkish households living with rare diseases

Kockaya¹,

Oğuzhan

Ökçün³

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

IntroductionThis study aims to determine the out-of-pocket health expenditures of households in Turkey where individuals with rare diseases are residing.MethodsThe research population consisted registered members of associations who are members of the Rare Diseases Network. In addition to the general analysis including all participants, expenditures based on characteristics of disease holders were also calculated.ResultsA total of 439 participants were included in the analysis. We determined that special nutrition was the highest expenditure group and emergency departments were the lowest expenditure group. When all the participants were evaluated, the average cost of rare diseases was found to be Ł22,743 (€2,877). A significant relationship was found between income status and out-of-pocket health expenditures (p = 0.012).DiscussionPolicy makers should consider inclusion of special nutritional products and medical/non-medical devices used in treatment of rare diseases within the scope of reimbursement and the development of orphan drug legislation as the first actions to be taken.

show abstract

Section: Discussionmentioning

confidence: 99%

Out-of-pocket healthcare expenditures of Turkish households living with rare diseases

Kockaya¹,

Oğuzhan

Ökçün³

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…For this work, six relevant criteria were identified, and a ranking is provided among seven IITs for performance improvement of the Indian higher education system. Özgür et al [ 240 ] examined and reviewed the healthcare policies of eighteen countries considering different health policy indicators comparing COPRAS, MOORA, and TOPSIS methods. The results suggest the best-performing nations, such as Germany and France, while Turkey is at the bottom, requiring improved health policies related to a rare disease.…”

Section: Application Areasmentioning

confidence: 99%

A historical review and analysis on MOORA and its fuzzy extensions for different applications

Singh,

Pathak,

Kumar

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Although studies with MCDM methods for vaccines are limited, studies evaluate alternatives from various objective and sectors with MCDM methods. İnce and Güre, 11 have presented a study with MCDM methods to evaluate Organisation for Economic Co-operation and Development countries in terms of disease policies. Azdast et al 12 the mechanical and morphological properties of nanocomposite foams were investigated in terms of AHP.…”

Section: Highlightsmentioning

confidence: 99%

Evaluation of supply sustainability of vaccine alternatives with multi‐criteria decision‐making methods

YAZICI

Üner

DEMİR

et al. 2022

Health Planning & Management

View full text Add to dashboard Cite

Background:The treatment of the COVID-19 epidemic, whose contagious features are changing day by day, is the most current problem today throughout of the world. In order to be protected from COVID-19 and reduce its spread, it is of great importance to follow the rules such as mask, distance and hygiene. In addition, one of the most important ways to prevent the epidemic is to develop population immunity. The most important tool in having population immunity is vaccination.Aims: During the COVID-19 pandemic, there have been problems in the supply process of many products in food and health sectors. Vaccine is also one of the most difficult tools to supply. In this context, the study focused on the selection of the vaccine provided by the countries within the scope of population vaccination studies.Materials & Methods: At the selection point, the criteria affecting the purchasing process were determined and the weights of these criteria were calculated using the AHP method. Then, the criteria weights obtained were used to rank the alternatives in an integrated manner in the Preference Ranking Organization Method for Enrichment of Evaluations (PROMETHEE) and Technique for Order Preference by Similarity to Ideal Solution (TOPSIS) methods. The results of both methods were analyzed comparatively.

show abstract

Evaluation of rare diseases policy performance of oecd countries using mcdm methods

Cited by 7 publications

References 16 publications

Out-of-pocket healthcare expenditures of Turkish households living with rare diseases

Out-of-pocket healthcare expenditures of Turkish households living with rare diseases

A historical review and analysis on MOORA and its fuzzy extensions for different applications

Evaluation of supply sustainability of vaccine alternatives with multi‐criteria decision‐making methods

Contact Info

Product

Resources

About